

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
11 June 2020 (11.06.2020)



(10) International Publication Number
WO 2020/115093 A1

(51) International Patent Classification:

A61P 25/00 (2006.01) *A61P 25/02* (2006.01)
C07D 207/27 (2006.01) *A61P 25/24* (2006.01)
A61K 31/4015 (2006.01) *A61P 25/28* (2006.01)

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/EP2019/083594

(22) International Filing Date:

04 December 2019 (04.12.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

18210106.3 04 December 2018 (04.12.2018) EP

(71) Applicant: **METYS PHARMACEUTICALS AG**
[CH/CH]; Gerbergasse 30, 4001 Basel (CH).

(72) Inventors: **FARINA, Carlo**; Via Mario Donati, 8, 20146 Milano (IT). **SCHERZ, Michael**; Benkenstrasse 48, 4140 Oberwil (CH). **GHELARDINI, Carla**; Via Bastianaccio, 21, 51100 Pistoia (IT). **DI CESARE MANNELLI, Lorenzo**; Via Cesare Bablo, 62, 59100 Prato (IT).

(74) Agent: **VOSSIUS & PARTNER (NO 31)**; Siebertstraße 3, 81675 München (DE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SYNERGISTIC COMPOSITIONS COMPRISING (R)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE AND (S)-2-(2-OXOPYRROLIDIN-1-YL)BUTANAMIDE IN A NON-RACEMIC RATIO

(57) Abstract: The present invention relates to a composition of the enantiomers of 2-(2-oxopyrrolidin-1-yl)butanamide and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from seizure-related disorders, peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.



WO 2020/115093 A1